Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Suriname Tech News.
Press releases published on April 2, 2025
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of …
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire
·
April 2, 2025
NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer …
Lantronix Named to CRN 2025 Internet of Things 50 List
GlobeNewswire
·
April 2, 2025
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced it has been recognized on the 2025 Internet of Things (IoT) 50 …
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
GlobeNewswire
·
April 2, 2025
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) …
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
GlobeNewswire
·
April 2, 2025
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, …
Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien-être, ainsi qu'un acteur clé sur le …
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, …
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
GlobeNewswire
·
April 2, 2025
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 …
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and …
Sophos Report: In 56% of Sophos IR and MDR Cases, Adversaries Logged In, Instead of Breaking In
GlobeNewswire
·
April 2, 2025
IR and MDR Cases Highlight Attackers Are Exfiltrating Data in Just Three Days Compromised Credentials Top Root Causes for Second Year OXFORD, U.K., April 02, 2025 (GLOBE NEWSWIRE) -- Sophos, a global leader of innovative security solutions for defeating …
lowRISC and SCI Semiconductor Release Sunburst Chip Repository for Secure Microcontroller Development
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, United Kingdom, April 02, 2025 (GLOBE NEWSWIRE) -- lowRISC C.I.C., the open silicon ecosystem organisation, together with SCI Semiconductor, a leader in CHERI solutions and both CHERI Alliance founding members, today announced the release of the …
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
GlobeNewswire
·
April 2, 2025
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold …
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire
·
April 2, 2025
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
MISE À JOUR--Décideurs politiques mondiaux et géants de la technologie se réuniront à Abou Dhabi pour l’édition inaugurale du Sommet sur la Gouvernance des Technologies Émergentes
GlobeNewswire
·
April 2, 2025
ABU DHABI, Émirats arabes unis, 02 avr. 2025 (GLOBE NEWSWIRE) -- Le Conseil de recherche sur les technologies avancées (ATRC) des Émirats Arabes Unis a annoncé aujourd'hui le lancement de la première édition du Sommet sur la Gouvernance des Technologies …
Global NK Cell Therapy Clinical Trials FDA Approval Patent Market Size Report 2025
GlobeNewswire
·
April 2, 2025
Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations and Market Opportunity Insight 2025 Report Highlights and Findings: Global …
XRP News: XRPTurbo Ends Oversubscribed Presale, Set For Bitmart Listing — Don’t Miss This $XRP Next Big Gem!
GlobeNewswire
·
April 2, 2025
TALLINN, Estonia, April 02, 2025 (GLOBE NEWSWIRE) -- The XRPTurbo presale has officially sold out, securing over 300,000 XRP in under 30 days—making waves as the hottest launchpad project in the XRP Ledger ecosystem. If you missed out, there’s no time for …
XRP Whale Interest Surges in $BLOC Seed Sale as BlocScale Launchpad Becomes the Go-To Platform for Asset Tokenization — Join $BLOC Seed Round
GlobeNewswire
·
April 2, 2025
LIJA, Malta, April 02, 2025 (GLOBE NEWSWIRE) -- BlocScale Launchpad, the first decentralized IDO platform built natively on the XRP Ledger, is witnessing a rapid influx of investor interest, most notably from crypto whales following its bold mission to …
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
GlobeNewswire
·
April 2, 2025
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemia Final European Commission decision expected by June 2025; UK regulatory submission foreseen via …
Inc. Names Aerospike to Its 2025 List of the Fastest-Growing Private Companies in the Pacific
GlobeNewswire
·
April 2, 2025
MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Aerospike, Inc. today announced its inclusion in the annual Inc. Regionals: Pacific list. An extension of the national Inc. 5000 list, this prestigious ranking features the fastest-growing private …
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
GlobeNewswire
·
April 2, 2025
Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced the …